R&D 5 changes underway for R&D IT shifting to advanced modalitie... Back in 2000, the FDA approved only six biologics versus 27 new molecular entities (NMEs).
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
